CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 721 enrolled
Drug / intervention
Fibrocaps +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01527357
NCT01527357Phase 3Completed

A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Hemostasis

Mallinckrodt·interventional·Posted Feb 7, 2012·Updated Dec 18, 2019

In Brief

A Phase 3 clinical trial evaluating Fibrocaps and Gelatin sponge for Mild or Moderate Surgical Bleeding. Completed, enrolled 721 participants across 48 sites in 4 countries.

Detailed Summary

The purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, for achieving hemostasis. The investigational products were used in participants with mild to moderate surgical bleeding during spine, liver, vascular or soft tissue surgery, when control of mild to moderate bleeding by standard surgical techniques is ineffective and/or impractical.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Netherlands, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 7, 2012
Enrollment StartMay 21, 2012
Primary CompletionApr 24, 2013
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.4 years ago

Interventions

Fibrocapsbiological

Human fibrinogen and thrombin powder, for topical administration.

Gelatin spongebiological

Absorbable gelatin sponge for topical administration.